LEILA RAFLA-DEMETRIOUS, MD
Glaucoma Specialist (Ophthalmology) Physician in NEW YORK, New York. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What stands out: LEILA RAFLA-DEMETRIOUS, MD reported a CMS MIPS final score of 100 out of 100, above the 83.1 national average, and filed 3,017 Medicare Part D claims in 2023. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.
LEILA RAFLA-DEMETRIOUS, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
LEILA RAFLA-DEMETRIOUS, MD at a glance
High performer (top quartile)Primary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in New York
How Glaucoma Specialist (Ophthalmology) Physician compares to other specialties among New York providers
Glaucoma Specialist (Ophthalmology) Physician share within New York
Glaucoma Specialist (Ophthalmology) Physician is one of the more visible NUCC categories in New York
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
LEILA RAFLA-DEMETRIOUS, MD's 2023 MIPS final score plotted against the Glaucoma Specialist (Ophthalmology) Physician national average
- MIPS Final Score
- 100/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Glaucoma Specialist (Ophthalmology) Physician) — 100/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Specialty volume Glaucoma Specialist (Ophthalmology) Physician US NPIs
100/100 MIPS final score — 16.9 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Glaucoma Specialist (Ophthalmology) Physician. Quality dim: 86.8066.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
LEILA RAFLA-DEMETRIOUS, MD is a Glaucoma Specialist (Ophthalmology) Physician provider practicing in NEW YORK, New York, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: MD. NPI: 1336236405. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.
LEILA RAFLA-DEMETRIOUS, MD appears in the CMS NPPES registry as a Glaucoma Specialist (Ophthalmology) Physician provider holding MD credentials at 1305 YORK AVE, NEW YORK, NY, 10021, with a listed phone of (646) 962-2020. NPI 1336236405 was issued on 10/09/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what RAFLA-DEMETRIOUS most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 3,017 prescription claims written by this provider, covering 456 Medicare beneficiaries and totaling roughly $739K in drug spend, split 51% brand-name and 49% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 100/100 for the 2023 performance year (Quality 86.8066), compared with the national average of 83.1.
Glaucoma Specialist (Ophthalmology) Physician is a narrow specialty nationwide, with 354 enrolled providers across 42 states and an average of 2,962 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1336236405 |
|---|---|
| Specialty | Glaucoma Specialist (Ophthalmology) Physician |
| Credentials | MD |
| Gender | Female |
| NPI Issued | 10/09/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm LEILA RAFLA-DEMETRIOUS, MD's current license status, disciplinary history, and board certifications with the New York State Education Department, Office of the Professions in New York before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Alternative Payment Model
Hospital and facility affiliations
Facilities where LEILA RAFLA-DEMETRIOUS, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
License & disciplinary context — New York NYSBPMC 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 — they are NOT specific to LEILA RAFLA-DEMETRIOUS, MD. To verify LEILA RAFLA-DEMETRIOUS, MD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
51% brand-name claims vs 49% generic, on 3,017 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 5,291
- Total Day Supply
- 152,628
- Brand vs Generic
- 51% brand / 49% generic
- Brand Drug Cost
- $648K
- Generic Drug Cost
- $91K
Patient Demographics
- Average Patient Age
- 76.5 years
- Avg HCC Risk Score
- 1.34
- Gender Split
- 69% female / 31% male
- Age Distribution
- <65: 24, 65-74: 160, 75-84: 196, 85+: 76
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
| Drug | Claims |
|---|---|
| Lumigan Bimatoprost | 436 |
| Latanoprost | 420 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 319 |
| Timolol Maleate | 248 |
| Prednisolone Acetate | 131 |
| Combigan Brimonidine Tartrate/Timolol | 128 |
| Alphagan P Brimonidine Tartrate | 105 |
| Travoprost | 102 |
| Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol | 97 |
| Ketorolac Tromethamine | 91 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Glaucoma Specialist (Ophthalmology) Physician Overview
How LEILA RAFLA-DEMETRIOUS, MD fits within the Glaucoma Specialist (Ophthalmology) Physician landscape nationally.
LEILA RAFLA-DEMETRIOUS, MD's 3,017 claims are above the specialty average of 2,962.
Nearby Glaucoma Specialist (Ophthalmology) Physician Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as RAFLA-DEMETRIOUS.
Compare Glaucoma Specialist (Ophthalmology) Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore New York
Frequently Asked Questions
What is LEILA RAFLA-DEMETRIOUS, MD's specialty? ▼
How much does LEILA RAFLA-DEMETRIOUS, MD prescribe under Medicare Part D? ▼
What is LEILA RAFLA-DEMETRIOUS, MD's Medicare quality score? ▼
Where is LEILA RAFLA-DEMETRIOUS, MD located? ▼
What is LEILA RAFLA-DEMETRIOUS, MD's NPI number? ▼
Does LEILA RAFLA-DEMETRIOUS, MD prescribe more brand-name or generic drugs? ▼
How many Glaucoma Specialist (Ophthalmology) Physician providers are there in the US? ▼
What drugs does LEILA RAFLA-DEMETRIOUS, MD prescribe most often? ▼
Does LEILA RAFLA-DEMETRIOUS, MD accept Medicare? ▼
How can I verify LEILA RAFLA-DEMETRIOUS, MD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology